This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at <u>www.tga.gov.au/reporting-problems</u>.

AUSTRALIAN PRODUCT INFORMATION – SCEMBLIX® (ASCIMINIB HYDROCHLORIDE) TABLETS

1 <u>NAME OF THE MEDICINE</u>

Asciminib hydrochloride

2 **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each 20 mg film-coated tablet contains 21.62 mg asciminib hydrochloride, which is equivalent to 20 mg asciminib.

Each 40 mg film-coated tablet contains 43.24 mg asciminib hydrochloride, which is equivalent to 40 mg asciminib.

SCEMBLIX tablets contain sugars as lactose and soyabean products.

For the full list of excipients, see Section 6.1 List of excipients.

3 PHARMACEUTICAL FORM

- 20 mg film-coated tablets: pale yellow, round, biconvex, film-coated tablets with beveled edges, approximately 6.2 mm diameter, unscored, debossed with "Novartis" logo on one side and "20" on the other side.
- 40 mg film-coated tablets: violet white, round, biconvex, film-coated tablets with beveled edges, approximately 8.2 mm diameter, unscored, debossed with "Novartis" logo on one side and "40" on the other side.

4 <u>CLINICAL PARTICULARS</u>

4.1 **THERAPEUTIC INDICATIONS**

SCEMBLIX is indicated for the treatment of patients 18 years of age and above with:

- Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase (CP)
- Ph+ CML in CP previously treated with two or more tyrosine kinase inhibitors.
- Ph+ CML in CP with the T315I mutation.

(see section 5.1 Clinical trials)

4.2 DOSE AND METHOD OF ADMINISTRATION

Treatment with SCEMBLIX should be initiated by a physician experienced in the use of anticancer therapies and should be continued as long as clinical benefit is observed or until unacceptable toxicity occurs.

Dose regimen

Ph+ CML-CP

The recommended total daily dose of SCEMBLIX is 80 mg.

SCEMBLIX can be taken orally either as 80 mg once daily at approximately the same time each day, or as 40 mg twice daily at approximately 12-hour intervals.

Patients changing from 40 mg twice daily to 80 mg once daily should start taking SCEMBLIX once daily approximately 12 hours after the last twice-daily dose and then continue at 80 mg once daily.

Patients changing from 80 mg once daily to 40 mg twice daily should start taking SCEMBLIX twice daily approximately 24 hours after the last once-daily dose and then continue at 40 mg twice daily at approximately 12-hour intervals.

Any change in the dosage regimen is at the prescriber's discretion, as necessary for the management of the patient.

Ph+ CML CP harbouring the T315I mutation

The recommended dose of SCEMBLIX is 200 mg taken orally twice daily at approximately 12 hour intervals.

Missed dose

Once-daily dosage regimen: If a SCEMBLIX dose is missed by more than approximately 12 hours, it should be skipped and the next dose should be taken as scheduled.

Twice-daily dosage regimen: If a SCEMBLIX dose is missed by more than approximately 6 hours, it should be skipped and the next dose should be taken as scheduled.

Dose modifications

Ph+ CML

For the management of adverse drug reactions, SCEMBLIX dose can be reduced based on individual safety and tolerability, as described in Table 1. If adverse drug reactions are effectively managed, SCEMBLIX may be resumed as described in Table 1.

SCEMBLIX should be permanently discontinued in patients unable to tolerate a total daily dose of 40 mg.

Ph+ CML-CP harbouring the T315I mutation

For the management of adverse drug reactions, SCEMBLIX dose can be reduced based on individual safety and tolerability, as described in Table 1. If adverse drug reactions are effectively managed, SCEMBLIX may be resumed as described in Table 1.

SCEMBLIX should be permanently discontinued in patients unable to tolerate a dose of 160 mg twice daily.

Table 1 SCEMBLIX dosage modification

Starting dose	Reduced dose	Resumed dose	
80 mg once daily	40 mg once daily	80 mg once daily	
40 mg twice daily	20 mg twice daily	40 mg twice daily	
200 mg twice daily	160 mg twice daily	200 mg twice daily	

The recommended dosage modification for the management of selected adverse drug reactions is shown in Table 2.

Table 2	SCEMBLIX dosage modification for the management of selected adverse drug
	reactions

Adverse drug reaction	Dosage modification
Thrombocytopaenia and/or neutropaenia	1
ANC ¹ <1 x 10 ⁹ /L and/or PLT ² <50 x 10 ⁹ /L	Withhold SCEMBLIX until resolved to ANC $\geq 1 \ge 10^{9}$ /L and/or PLT $\geq 50 \ge 10^{9}$ /L.
	If resolved:
	• Within 2 weeks: resume SCEMBLIX at starting dose.
	• After more than 2 weeks: resume SCEMBLIX at reduced dose.
	For recurrent severe thrombocytopaenia and/or neutropaenia, withhold SCEMBLIX until resolved to ANC $\geq 1 \ge 10^{9}$ /L and PLT $\geq 50 \ge 10^{9}$ /L, then resume at reduced dose.
Asymptomatic amylase and/or lipase elev	vation
Elevation $>2 \text{ x ULN}^3$	Withhold SCEMBLIX until resolved to <1.5 x ULN.
	• If resolved: resume SCEMBLIX at reduced dose. If events reoccur at reduced dose, permanently discontinue SCEMBLIX.
	• If not resolved: permanently discontinue SCEMBLIX. Perform diagnostic tests to exclude pancreatitis.
Non-haematologic adverse drug reaction	s
Grade 3 or higher ⁴ adverse reactions	Withhold SCEMBLIX until resolved to Grade 1 or lower ⁴ .
	• If resolved: resume SCEMBLIX at a reduced dose.
	• If not resolved: permanently discontinue SCEMBLIX.
¹ ANC: absolute neutrophil count; ² PLT: pla	telets; ³ ULN: upper limit of normal.

⁴Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 4.03.

Method of administration

SCEMBLIX should be taken orally without food. Food consumption should be avoided for at least 2 hours before and 1 hour after taking SCEMBLIX (see section 4.5 Interactions with other medicines and other forms of interactions and section 5.2 Pharmacokinetic properties).

SCEMBLIX film-coated tablets should be swallowed whole and should not be broken, crushed or chewed.

Special populations

Hepatic impairment

No dose adjustment is required in patients with mild, moderate or severe hepatic impairment receiving SCEMBLIX. Caution should be exercised in patients with severe hepatic impairment receiving SCEMBLIX 200 mg twice daily dose (see section 5.2 Pharmacokinetic properties).

Renal impairment

No dose adjustment is required in patients with mild, moderate or severe renal impairment receiving SCEMBLIX. Caution should be exercised in patients with severe renal impairment receiving SCEMBLIX 200 mg twice daily dose (see section 5.2 Pharmacokinetic properties).

Paediatric patients (below 18 years)

The safety and efficacy of SCEMBLIX in paediatric patients (below 18 years) has not been established.

Elderly patients (65 years of age or above)

No dose adjustment is required in patients 65 years of age or above.

4.3 CONTRAINDICATIONS

Known hypersensitivity to the active substance asciminib or to any of the excipients listed in section 6.1.

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Identified precautions

Myelosuppression

Thrombocytopaenia, neutropaenia and anaemia occurred in patients receiving SCEMBLIX. Severe (NCI CTCAE grade 3 or 4) thrombocytopaenia and neutropaenia reactions were reported during treatment with SCEMBLIX (see section 4.8 Adverse effects (undesirable effects)).

Myelosuppression was generally reversible and managed by temporarily withholding SCEMBLIX. Complete blood counts should be performed every two weeks for the first 3 months of treatment and monthly thereafter, or as clinically indicated. Patients should be monitored for signs and symptoms of myelosuppression.

Based on the severity of thrombocytopaenia and/or neutropaenia, the SCEMBLIX dose should be reduced, temporarily withheld or permanently discontinued as described in Table 2 (see section 4.2 Dose and method of administration).

Pancreatic toxicity

Clinical pancreatitis events occurred in 11 of 556 (2%) patients receiving SCEMBLIX, with grade 3 reactions occurring in 6 (1.1%) patients. Scemblix was permanently discontinued in 3 (0.5%) patients, while it was temporarily withheld in 6 (1.1%) patients due to pancreatitis. Asymptomatic elevation of serum lipase and amylase occurred in 107 of 556 (19.2%) patients receiving SCEMBLIX (see also Table 3, "pancreatitis enzymes increased"), with grade 3 and 4 reactions occurring in 41 (7.4%) and 11 (2%) patients, respectively. SCEMBLIX was

permanently discontinued in 11 (2%) patients due to the symptomatic elevation of serum lipase and amylase.

Serum lipase and amylase levels should be assessed monthly during treatment with SCEMBLIX, or as clinically indicated. Patients should be monitored for signs and symptoms of pancreatic toxicity. More frequent monitoring should be performed in patients with a history of pancreatitis. If serum lipase and amylase elevation are accompanied by abdominal symptoms, treatment should be temporarily withheld and appropriate diagnostic tests should be considered to exclude pancreatitis (see section 4.2 Dose and method of administration).

Based on the severity of serum lipase and amylase elevation, the SCEMBLIX dose should be reduced, temporarily withheld or permanently discontinued as described in Table 2 (see section 4.2 Dose and method administration).

QT prolongation

Electrocardiogram QT prolongation occurred in 5 of 556 (0.9%) patients receiving SCEMBLIX (see section 4.8 Adverse effects (Undesirable effects)). In the ASCEMBL clinical study, one patient had a prolonged QTcF greater than 500 ms together with more than 60 ms QTcF increase from baseline and one patient had prolonged QTcF with more than 60 ms QTcF increase from baseline.

It is recommended that an electrocardiogram is performed prior to the start of treatment with SCEMBLIX and monitored during treatment as clinically indicated. Hypokalaemia and hypomagnesaemia should be corrected prior to SCEMBLIX administration and monitored during treatment as clinically indicated.

Caution should be exercised when administering SCEMBLIX at a total daily dose of 80 mg concomitantly with medicinal products with a known risk of torsades de pointes. Co-administration of SCEMBLIX at 200 mg twice daily concomitantly with medicinal products with a known risk of torsades de pointes should be avoided (See section 4.5 Interactions with other medicines and other forms of interactions and section 5.1 Pharmacodynamic properties).

Hypertension

Hypertension occurred in 88 of 556 (15.8%) patients receiving SCEMBLIX, with grade 3 and 4 reactions reported in 47 (8.5%) and 1 (0.2%) patients, respectively. Among the patients with hypertension \geq grade 3, the median time to first occurrence of reactions was 21.29 weeks (range: 0.14 to 365 weeks). SCEMBLIX was temporarily withheld in 5 (0.9%) patients due to hypertension.

Hypertension should be monitored and managed using standard antihypertensive therapy during treatment with SCEMBLIX as clinically indicated.

For Grade 3 or higher hypertension, temporarily withhold, reduce dose, or permanently discontinue SCEMBLIX depending on persistence of hypertension (see section 4.2 Dose and method of administration).

Hypersensitivity

Hypersensitivity events occurred in 169 of 556 (30.4%) patients receiving SCEMBLIX, with \geq grade 3 events reported in 8 (1.4%) patients. Patients should be monitored for signs and symptoms of hypersensitivity and appropriate treatment should be initiated as clinically indicated.

Hepatitis B reactivation

Reactivation of hepatitis B virus (HBV) has occurred in patients who are chronic carriers of this virus following administration of other BCR::ABL1 tyrosine kinase inhibitors (TKIs). Patients should be tested for HBV infection before the start of treatment with SCEMBLIX. HBV carriers who require treatment with SCEMBLIX should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy.

Embryo-fetal toxicity

Based on findings from animal studies, SCEMBLIX can cause fetal harm when administered to a pregnant woman. Pregnant women and females of reproductive potential should be advised of the potential risk to a fetus if SCEMBLIX is used during pregnancy or if the patient becomes pregnant while taking SCEMBLIX. The pregnancy status of females of reproductive potential should be verified prior to starting treatment with SCEMBLIX. Sexually-active females of reproductive potential should use effective contraception during treatment with SCEMBLIX and for at least 3 days after the last dose (see section 4.6 Fertility, pregnancy and lactation).

Use in hepatic impairment

See section 5.2, Pharmacokinetic properties, special populations.

Use in renal impairment

See section 5.2, Pharmacokinetic properties, special populations.

Use in the elderly

See section 5.2, Pharmacokinetic properties, special populations.

Paediatric use

The safety and efficacy of SCEMBLIX in paediatric patients (below 18 years) has not been established.

Effects on laboratory tests

See section 4.8 (adverse effects (undesirable effects)).

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

Agents that may increase asciminib plasma concentrations

Strong CYP3A4 inhibitors

Physiologically-based pharmacokinetic (PBPK) models predict that co-administration of SCEMBLIX at 200 mg twice daily with a strong CYP3A4 inhibitor (clarithromycin) would increase asciminib AUCtau and Cmax by 77% and 49%, respectively.

Caution should be exercised during concomitant administration of SCEMBLIX 200 mg twice daily with strong CYP3A4 inhibitors including but not limited to clarithromycin, telithromycin, troleandomycin, itraconazole, ketoconazole, voriconazole, ritonavir, indinavir, nelfinavir or saquinavir. Dose adjustment of SCEMBLIX is not required.

Agents that may decrease asciminib plasma concentrations

Strong CYP3A4 inducers

Co-administration of a strong CYP3A4 inducer (rifampicin) decreased asciminib AUCinf by 14.9%, while increasing asciminib Cmax by 9% in healthy subjects receiving a single SCEMBLIX dose of 40 mg. Co-administration of a strong CYP3A4 inducer (phenytoin) decreased asciminib AUCinf and Cmax by 34% and 22%, respectively, in healthy subjects receiving a single SCEMBLIX dose of 200 mg.

Caution should be exercised during concomitant administration of SCEMBLIX at all recommended doses with strong CYP3A4 inducers, including but not limited to carbamazepine, phenobarbital, phenytoin or St. John's wort *(Hypericum perforatum)*. Dose adjustment of SCEMBLIX is not required.

Agents that may have their plasma concentrations altered by asciminib

CYP3A4 substrates with narrow therapeutic index

Asciminib is a CYP3A4 inhibitor. Concomitant use of SCEMBLIX increases the Cmax and AUC of CYP3A4 substrates, which may increase the risk of adverse reactions of these substrates.

Co-administration of asciminib with a CYP3A4 substrate (midazolam) increased midazolam AUCinf and Cmax by 28% and 11%, respectively, in healthy subjects receiving SCEMBLIX 40 mg twice daily.

PBPK models predict that co-administration of asciminib at 80 mg once daily would increase midazolam AUCinf and Cmax by 24% and 17%, respectively, while co-administration of asciminib at 200 mg twice daily would increase midazolam AUCinf and Cmax by 88% and 58%, respectively.

Caution should be exercised during concomitant administration of SCEMBLIX at all recommended doses with CYP3A4 substrates known to have a narrow therapeutic index, including, but not limited to, the CYP3A4 substrates fentanyl, alfentanil, dihydroergotamine, or ergotamine. Dose adjustment of SCEMBLIX is not required.

CYP2C9 substrates

Asciminib is a CYP2C9 inhibitor. Concomitant use of SCEMBLIX increases the Cmax and AUC of CYP2C9 substrates, which may increase the risk of adverse reactions of these substrates.

Co-administration of asciminib with a CYP2C9 substrate (warfarin) increased S-warfarin AUCinf and Cmax by 41% and 8%, respectively, in healthy subjects receiving SCEMBLIX 40 mg twice daily.

PBPK models predict that co-administration of asciminib at 80 mg once daily would increase S-warfarin AUCinf and Cmax by 52% and 4%, respectively, while co-administration of asciminib at 200 mg twice daily would increase S-warfarin AUCinf and Cmax by 314% and 7%, respectively.

Caution should be exercised during concomitant administration of SCEMBLIX at 80mg total daily dose with CYP2C9 substrates known to have a narrow therapeutic index, including, but not limited to phenytoin or warfarin. Dose adjustment of SCEMBLIX is not required.

Concomitant administration of SCEMBLIX at 200 mg twice daily with CYP2C9 sensitive substrates and CYP2C9 substrates known to have a narrow therapeutic index should be avoided and alternative medications should be considered. If co-administration cannot be avoided, the CYP2C9 substrates dose should be reduced. If co-administration with warfarin cannot be avoided, the frequency of international normalized ratio (INR) monitoring should be increased as the anti-coagulant effect of warfarin may be enhanced.

Substrates of OATP1B or BCRP

Asciminib is an OATP1B and BCRP inhibitor. The effect of concomitant use of SCEMBLIX with OATP1B and BCRP substrates has not been established in clinical studies. However, based upon a mechanistic understanding of the elimination of asciminib and its *in vitro* inhibitory potential, concomitant use of SCEMBLIX increases the Cmax and AUC of OATP1B and BCRP substrates, which may increase the risk of adverse reactions of these substrates (refer section 5.1 Pharmacodynamic properties).

Co-administration of asciminib at 80 mg once daily with an OATP1B, CYP3A4 and P-gp substrate (atorvastatin) increased atorvastatin AUCinf and Cmax by 14% and 24%, respectively, in healthy subjects.

Avoid concomitant administration of SCEMBLIX at all recommended doses with rosuvastatin and consider alternative statins. If co-administration cannot be avoided, rosuvastatin dose should be reduced, as recommended in its product information.

Caution should be exercised during concomitant administration of SCEMBLIX at all recommended doses with substrates of OATP1B, BCRP or both transporters, including, but not limited to sulfasalazine, methotrexate, pravastatin, atorvastatin, and simvastatin. Refer to OATP1B and BCRP substrates' dose reductions, as recommended in their prescribing information. Closely monitor for adverse reactions during concomitant use of SCEMBLIX at all recommended doses.

P-gp substrates of narrow therapeutic index

PBPK models predict that co-administration of asciminib at 40 mg twice daily and 80 mg once daily with a P-gp substrate (digoxin) would increase digoxin Cmax by 30% and 38% and AUCinf by 20% and 22%, respectively, while co-administration of asciminib at 200 mg twice daily would increase digoxin Cmax and AUCinf by 62% and 40%, respectively.

Caution should be exercised during concomitant administration of Scemblix at all recommended doses with P-gp substrates known to have a narrow therapeutic index, including but not limited to digoxin, dabigatran, and colchicine.

In vitro evaluation of drug interaction potential

In vitro, asciminib reversibly inhibits CYP3A4/5, CYP2C9, CYP2C8, CYP2B6, CYP2C19, UGT1A1 and UGT2B7.

Transporters

Asciminib is a substrate of BCRP and P-gp. *In vitro*, asciminib inhibits BCRP, P-gp, OATP1B1, OATP1B3, OCT1, OCT2, OAT1, OAT3, MATE1, MATE2. Based on PBPK models, asciminib increased the exposure of P-gp, OATP1B and BCRP substrates (see "Substrates of OATP1B, of BCRP or of both transporters" above). The clinical relevance of the interaction with OCT1 is currently unknown at SCEMBLIX 200 mg twice daily dosing.

Multiple pathways

Asciminib is metabolised by several pathways including the CYP3A4, UGT2B7 and UGT2B17 enzymes and biliary secreted by the transporter BCRP.

Medicinal products inhibiting or inducing multiple pathways may alter SCEMBLIX exposure.

Asciminib inhibits several pathways including CYP3A4, CYP2C9, OATP1B, P-gp and BCRP. SCEMBLIX may increase the exposure of medicinal products, which are substrates of these pathways (see subsection "Substrates of OATP1B, of BCRP or of both transporters" above).

QT prolonging agents

Caution should be exercised during concomitant administration of SCEMBLIX at 80 mg total daily dose and medicinal products with a known risk of torsades de pointes, including, but not limited to, bepridil, chloroquine, clarithromycin, halofantrine, haloperidol, methadone, moxifloxacin or pimozide (see section 5.2 Pharmacokinetic properties).

Concomitant administration of SCEMBLIX at 200 mg twice daily dose and medicinal products with a known risk of torsades de pointes should be avoided (see section 5.2 Pharmacokinetic properties).

Drug-food interactions

The bioavailability of asciminib decreases on consumption of food (see sections 4.2 Dose and method of administration and section 5.2 Pharmacokinetic properties).

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on fertility

There are no data on the effect of SCEMBLIX on human fertility.

In the rat fertility study, asciminib administered via the oral route at doses of 200 mg/kg/day did not affect reproductive function in male and female rats. A slight effect on male sperm motility and sperm count was observed at doses of 200 mg/kg/day, likely at AUC exposures 19-fold, 13-fold or 2-fold higher than those achieved in patients at the 40 mg twice-daily, 80 mg once-daily or 200 mg twice daily doses, respectively.

Use in pregnancy – Pregnancy Category D

Risk summary

Based on findings from animal studies, SCEMBLIX can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women to inform a product-associated risk.

Animal reproduction studies in pregnant rats and rabbits demonstrated that oral administration of asciminib during organogenesis induced embryotoxicity, fetotoxicity and teratogenicity. In embryofetal development studies, pregnant animals received oral doses of asciminib at 25, 150 and 600 mg/kg/day in rats and at 15, 50 and 300 mg/kg/day in rabbits during the period of organogenesis.

In rats, increases in fetal malformations (anasarca, cleft palate, cardiomegaly, pericardium filled with fluid and stenosis of the aortic arch) were noted at 150 mg/kg/day (AUC exposures 13-fold higher than those achieved in patients at the 40 mg twice daily or 80 mg once-daily doses) and

increased fetal weights at 25 mg/kg/day (AUC exposures equal to those achieved in patients at the 40 mg twice daily or 80 mg once daily doses) in the absence of adverse maternal effects. At the fetal maternal no-observed-adverse-effect level of 25 mg/kg/day, the AUC exposures were below those achieved in patients at the 200 mg twice daily dose.

In rabbits, dosed at 50 mg/kg/day (AUC exposures 4-fold higher than those achieved in patients at the 40 mg twice daily or 80 mg once daily doses), increased incidence of resorptions, indicative of embryofetal mortality and incidence of cardiac malformations (including dilated aorta/aortic arch, truncus arteriosus, valve absent, ventricular septum defect and/or atretic pulmonary artery, indicative of dysmorphogenesis) were observed. At the fetal maternal no-observed-adverse-effect level of 15 mg/kg/day, the AUC exposures were below those achieved in patients at the 200 mg twice daily dose.

All these effects were in absence of adverse maternal effects and were considered to be drug related.

Pregnant women and females of reproductive potential should be advised of the potential risk to a fetus if SCEMBLIX is used during pregnancy or if the patient becomes pregnant while taking SCEMBLIX (see section 4.4 Special warnings and precautions for use).

Pregnancy testing

The pregnancy status of females of reproductive potential should be verified prior to starting treatment with SCEMBLIX.

Contraception

Sexually-active females of reproductive potential should use effective contraception (methods that result in less than 1% pregnancy rates) during treatment with SCEMBLIX and for at least 3 days after the last dose.

Use in lactation.

It is not known if asciminib is transferred into human milk after administration of SCEMBLIX. There are no data on the effects of asciminib on the breastfed child or on milk production.

Because of the potential for serious adverse drug reactions in the breastfed child, breast-feeding is not recommended during treatment with SCEMBLIX and for at least 3 days after the last dose.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Summary of the safety profile

The overall safety profile of SCEMBLIX has been evaluated in 556 patients with Ph+ CML in chronic (CP) and accelerated (AP) phases receiving SCEMBLIX as monotherapy. It is based on the safety pool of the pivotal phase III study J12301 (ASC4FIRST) (N=200 newly diagnosed Ph+CML-CP patients), the pivotal phase III study A2301 (ASCEMBL) (N=156 Ph+ CML-CP patients previously treated with 2 or more TKIs) and the phase I study X2101, including patients with:

- Ph+ CML-CP (N=115),
- Ph+ CML-CP harbouring the T315I mutation (N=70),
- Ph+CML-AP (N=15).

The safety pool (N=556) includes patients receiving SCEMBLIX at doses ranging from 10 to 200 mg twice daily and 80 to 200 mg once daily. In the pooled dataset, the median duration of exposure to SCEMBLIX was 83.29 weeks (range: 0.1 to 439 weeks), with 79.3% of patients exposed for at least 48 weeks and 42.4% of patients exposed for at least 96 weeks, respectively.

The most common adverse drug reactions of any grade (incidence $\geq 20\%$) in patients receiving SCEMBLIX were musculoskeletal pain (32.9%), thrombocytopenia (28.1%), fatigue (25%), upper respiratory tract infections (23.7%), headache (21.8%), neutropenia (21.6%) and diarrhoea (20%).. The most common adverse drug reactions of \geq grade 3 (incidence $\geq 5\%$) in patients receiving SCEMBLIX were thrombocytopaenia (16.5%), neutropaenia (13.7%), increased pancreatic enzymes (9.4%) and hypertension (8.6%).

Serious adverse drug reactions occurred in 9.5% of patients receiving SCEMBLIX. The most frequent serious adverse drug reactions (incidence $\geq 1\%$) were pleural effusion (1.6%), lower respiratory tract infections (1.4%), thrombocytopaenia (1.3%), pancreatitis (1.1%) and pyrexia (1.1%).

Tabulated summary of adverse drug reactions from clinical trials

Adverse drug reactions from clinical studies (Table 3) are listed by MedDRA system organ class. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III): very common ($\geq 1/10$); common ($\geq 1/100$ to <1/10); uncommon ($\geq 1/1,000$ to <1/100); rare ($\geq 1/10,000$).

Table 3 Adverse drug reactions observed with SCEMBLIX in clinical studies

		All gra	Ides			Grade	e ≥3		All	grades
Adverse drug reactions	Scemblix 80 mg QD N=200 n (%)	IS-TKIs ¹ 100-400 mg QD or BID N=201 n (%)	Imatinib 400 mg QD N=99 n (%)	2G TKIs ¹ 100-400 mg QD or BID N=102 n (%)	Scemblix 80 mg QD1 N=200 n (%)	IS-TKIs ¹ 100-400 mg QD or BID N=201 n (%)	Imatinib 400 mg QD N=99 n (%)	2G TKIs ¹ 100-400 mg QD or BID N=102 n (%)	Scemblix safety pool ^{2,3} N=556 (%)	Frequency category ³ N=556 (%)
Infections and infe	stations							•		
Upper respiratory tract infection ⁴	27 (13.5)	29 (14.4)	16 (16.2)	13 (12.7)	0	1 (0.5)	1 (1)	0	132 (23.7)	Very Common
Lower respiratory tract infection ⁵	8 (4)	9 (4.5)	4 (4)	5 (4.9)	0	3 (1.5)	1 (1)	2 (2)	36 (6.5)	Common
Influenza	4 (2)	5 (2.5)	3 (3)	2 (2)	0	0	0	0	21 (3.8)	Common
Blood and lymphat	ic system diso	rders								
Thrombocyto- penia ⁶	56 (28)	63 (31.3)	28 (28.3)	35 (34.3)	26 (13)	20 (10)	6 (6.1)	14 (13.7)	156 (28.1)	Very Common
Neutropenia ⁷	50 (25)	66 (32.8)	31 (31.3)	35 (34.3)	20 (10)	35 (17.4)	17 (17.2)	18 (17.6)	120 (21.6)	Very Common
Anaemia ⁸	23 (11.5)	49 (24.4)	26 (26.3)	23 (22.5)	3 (1.5)	11 (5.5)	5 (5.1)	6 (5.9)	70 (12.6)	Very Common
Febrile neutropenia	1 (0.5)	0	0	0	1 (0.5)	0	0	0	4 (0.7)	Uncommon
Immune system dis	sorders									
Hypersensitivity	0	3 (1.5)	1 (1)	2 (2)	0	0	0	0	1 (0.2)	Uncommon
Endocrine disorder	ſS									
Hypothyroidism ⁹	5 (2.5)	1 (0.5)	1 (1)	0	0	0	0	0	10 (1.8)	Common
Metabolism and nu	trition disorder	S								
Dyslipidaemia ¹⁰	28 (14)	18 (9)	6 (6.1)	12 (11.8)	2 (1)	1 (0.5)	1 (1)	0	69 (12.4)	Very Common
Decreased appetite	5 (2.5)	10 (5)	4 (4)	6 (5.9)	0	1 (0.5)	1 (1)	0	31 (5.6)	Common
Nervous system di	sorders									
Headache	27 (13.5)	30 (14.9)	8 (8.1)	22 (21.6)	1 (0.5)	0	0	0	121 (21.8)	Very Common
Dizziness	8 (4)	8 (4)	2 (2)	6 (5.9)	0	0	0	0	61 (11)	Very Common

All grades				Grade ≥3				All grades		
Adverse drug reactions	Scemblix 80 mg QD N=200 n (%)	IS-TKIs ¹ 100-400 mg QD or BID N=201 n (%)	Imatinib 400 mg QD N=99 n (%)	2G TKIs ¹ 100-400 mg QD or BID N=102 n (%)	Scemblix 80 mg QD1 N=200 n (%)	IS-TKIs ¹ 100-400 mg QD or BID N=201 n (%)	Imatinib 400 mg QD N=99 n (%)	2G TKIs ¹ 100-400 mg QD or BID N=102 n (%)	Scemblix safety pool ^{2,3} N=556 (%)	Frequency category ³ N=556 (%)
Eye disorders										
Vision blurred	2 (1)	4 (2)	2 (2)	2 (2)	0	0	0	0	20 (3.6)	Common
Dry eye	11 (5.5)	8 (4)	4 (4)	4 (3.9)	0	0	0	0	32 (5.8)	Common
Cardiac disorders										
Palpitations	1 (0.5)	6 (3)	1 (1)	5 (4.9)	0	0	0	0	18 (3.2)	Common
Vascular disorders										
Hypertension ¹¹	14 (7)	8 (4)	6 (6.1)	2 (2)	8 (4)	5 (2.5)	3 (3)	2 (2)	88 (15.8)	Very Common
Respiratory, thorac	ic and mediast	inal disorders								
Cough	12 (6)	16 (8)	6 (6.1)	10 (9.8)	0	0	0	0	67 (12.1)	Very common
Pleural effusion	0	7 (3.5)	0	7 (6.9)	0	1 (0.5)	0	1 (1)	20 (3.6)	Common
Dyspnoea	1 (0.5)	6 (3)	2 (2)	4 (3.9)	0	0	0	0	37 (6.7)	Common
Non-cardiac chest pain	3 (1.5)	0	0	0	0	0	0	0	35 (6.3)	Common
Gastrointestinal dis	sorders									
Pancreatic enzymes increased ¹²	25 (12.5)	28 (13.9)	14 (14.1)	14 (13.7)	6 (3)	6 (3)	1 (1)	5 (4.9)	107 (19.2)	Very common
Vomiting	11 (5.5)	18 (9)	12 (12.1)	6 (5.9)	0	0	0	0	75 (13.5)	Very common
Diarrhoea	31 (15.5)	52 (25.9)	26 (26.3)	26 (25.5)	0	1 (0.5)	0	1 (1)	111 (20)	Very common
Nausea	18 (9)	39 (19.4)	21 (21.2)	18 (17.6)	0	0	0	0	92 (16.5)	Very common
Abdominal pain ¹³	25 (12.5)	18 (9)	6 (6.1)	12 (11.8)	1 (0.5)	0	0	0	104 (18.7)	Very common
Pancreatitis ¹⁴	2 (1)	2 (1)	2 (2)	0	2 (1)	1 (0.5)	1 (1)	0	11 (2)	Common
Hepatobiliary disor	ders	•		•	•	•	•	•	•	·

	All grades				Grade ≥3				All grades	
Adverse drug reactions	Scemblix 80 mg QD N=200 n (%)	IS-TKIs ¹ 100-400 mg QD or BID N=201 n (%)	Imatinib 400 mg QD N=99 n (%)	2G TKIs ¹ 100-400 mg QD or BID N=102 n (%)	Scemblix 80 mg QD1 N=200 n (%)	IS-TKIs ¹ 100-400 mg QD or BID N=201 n (%)	Imatinib 400 mg QD N=99 n (%)	2G TKIs ¹ 100-400 mg QD or BID N=102 n (%)	Scemblix safety pool ^{2,3} N=556 (%)	Frequency category ³ N=556 (%)
Hepatic enzyme increased ¹⁵	19 (9.5)	31 (15.4)	8 (8.1)	23 (22.5)	4 (2)	10 (5)	2 (2)	8 (7.8)	79 (14.2)	Very common
Blood bilirubin increased ¹⁶	7 (3.5)	15 (7.5)	2 (2)	13 (12.7)	0	1 (0.5)	1 (1)	0	25 (4.5)	Common
Skin and subcutan	eous tissue dis	orders								
Rash ¹⁷	30 (15)	37 (18.4)	12 (12.1)	25 (24.5)	0	4 (2)	2 (2)	2 (2)	107 (19.2)	Very common
Pruritus	13 (6.5)	7 (3.5)	4 (4)	3 (2.9)	0	0	0	0	58 (10.4)	Very common
Urticaria	5 (2.5)	5 (2.5)	0	5 (4.9)	0	0	0	0	18 (3.2)	Common
Musculoskeletal an	d connective ti	issue disorders	5							
Musculoskeletal pain ¹⁸	46 (23)	61 (30.3)	30 (30.3)	31 (30.4)	2 (1)	1 (0.5)	1 (1)	0	183 (32.9)	Very Common
Arthralgia	19 (9.5)	15 (7.5)	8 (8.1)	7 (6.9)	0	1 (0.5)	1 (1)	0	108 (19.4)	Very Common
General disorders	and administra	tion site condit	ions							
Fatigue ¹⁹	36 (18)	41 (20.4)	22 (22.2)	19 (18.6)	2 (1)	1 (0.5)	1 (1)	0	139 (25)	Very common
Oedema ²⁰	5 (2.5)	17 (8.5)	11 (11.1)	6 (5.9)	0	0	0	0	44 (7.9)	Common
Pyrexia ²¹	11 (5.5)	10 (5)	6 (6.1)	4 (3.9)	0	0	0	0	49 (8.8)	Common
Investigations					•					•
Blood creatine phosphokinase increased	10 (5)	11 (5.5)	4 (4)	7 (6.9)	4 (2)	2 (1)	0	2 (2)	23 (4.1)	Common
Electrocardiogram QT prolonged	1 (0.5)	2 (1)	0	2 (2)	1 (0.5)	0	0	0	5 (0.9)	Uncommon
¹ Investigator-selected	TKIs (IS-TKIs) inc	lude imatinib (400	mg once daily)	or second genera	ation (2G) TKIs, i.	e. nilotinib (300 m	g twice daily), d	asatinib (100 mg	once daily) or	bosutinib

(400 mg once daily). IS-TKIs median duration of exposure: 64.29 weeks (range: 1.3 to 103.1 weeks). 2G TKIs median duration of exposure: 71.43 weeks (range: 1.3 to 103.1 weeks) Imatinib median duration of exposure: 56.29 weeks (range: 2.7 to 99 weeks). ²Scemblix median duration of exposure: 83.29 weeks (range: 0.1 to 439 weeks). ³Frequency based on the safety pool (J12301, A2301 and X2101) for Scemblix all grade reactions (N=556).

		All gra	des			Grade	e ≥3		All g	grades
Adverse drug reactions	Scemblix 80 mg QD N=200 n (%)	IS-TKIs ¹ 100-400 mg QD or BID N=201 n (%)	Imatinib 400 mg QD N=99 n (%)	2G TKIs ¹ 100-400 mg QD or BID N=102 n (%)	Scemblix 80 mg QD1 N=200 n (%)	IS-TKIs ¹ 100-400 mg QD or BID N=201 n (%)	Imatinib 400 mg QD N=99 n (%)	2G TKIs ¹ 100-400 mg QD or BID N=102 n (%)	Scemblix safety pool ^{2,3} N=556 (%)	Frequency category ³ N=556 (%)

⁴Upper respiratory tract infection includes: upper respiratory tract infection, nasopharyngitis, pharyngitis and rhinitis; ⁵Lower respiratory tract infections includes: pneumonia, bronchitis and tracheobronchitis; ⁶Thrombocytopenia includes: thrombocytopenia and platelet count decreased; ⁷Neutropenia includes: neutropenia and neutrophil count decreased; ⁸Anaemia includes: anaemia and haemoglobin decreased; ⁹Hypothyroidism includes: hypothyroidism, autoimmune thyroiditis, blood thyroid stimulating hormone increased, autoimmune hypothyroidism and primary hypothyroidism; ¹⁰Dyslipidaemia includes: hypertriglyceridaemia, blood cholesterol increased, hypercholesterolaemia, blood triglycerides increased, hyperlipidaemia; ¹¹Hypertension includes: hypertension and blood pressure increased; ¹²Pancreatic enzymes increased includes: lipase increased, amylase increased and hyperlipiasaemia; ¹³Abdominal pain includes: abdominal pain upper; ¹⁴Pancreatitis includes: pancreatitis and pancreatitis and pancreatitis and pancreatitis and pancreatitis increased, aspartate aminotransferase increased and hyperbilirubinaemia; ¹⁷Rash includes: rash, rash maculopapular and rash pruritic; ¹⁸Musculoskeletal pain includes: pain in extremity, back pain, musculoskeletal chest pain, and musculoskeletal discomfort; ¹⁹Fatigue includes: fatigue and asthenia; ²⁰Oedema includes: portensed.

In the ASCEMBL study, decrease in phosphate levels occurred as a laboratory abnormality in 17.9% (all grades) and 7.1% (grade 3/4) of 156 patients receiving SCEMBLIX at 40 mg twice daily. In the ASC4FIRST study, decrease in phosphate levels based on normal ranges occurred as a laboratory abnormality in 13% (all grades) of 200 patients receiving Scemblix at 80 mg once daily.

Description of selected adverse drug reactions

Myelosuppression

Thrombocytopaenia occurred in 156 of 556 (28.1%) patients receiving SCEMBLIX, with grade 3 and 4 reactions reported in 39 (7%) and 53 (9.5%) of patients, respectively. Among the patients with thrombocytopaenia \geq grade 3, the median time to first occurrence of reactions was 6 weeks (range: 0.14 to 64.14 weeks) with median duration of any occurring reaction of 1.57 weeks (95% CI, range: 1.14 to 2 weeks). SCEMBLIX was permanently discontinued in 11 (2%) patients, while it was temporarily withheld in 70 (12.6%) patients due to thrombocytopenia.

Neutropaenia occurred in 120 of 556 (21.6%) patients receiving SCEMBLIX, with grade 3 and 4 reactions reported in 41 (7.4%) and 35 (6.3%) patients, respectively. Among the patients with neutropaenia \geq grade 3, the median time to first occurrence of reactions was 7.07 weeks (range: 0.14 to 180.14 weeks) with median duration of any occurring reaction of 1.86 weeks (95% CI, range: 1.29 to 2 weeks). SCEMBLIX was permanently discontinued in 7 (1.3%) patients, while it was temporarily withheld in 52 (9.4%) patients due to neutropenia.

Anaemia occurred in 70 of 556 (12.9%) patients receiving SCEMBLIX, with grade 3 reactions occurring in 22 (4%) patients. Among the patients with anaemia grade 3, the median time to first occurrence of reactions was 22.21 weeks (range: 0.14 to 207 weeks) with median duration of any occurring reaction of 0.79 weeks (95% CI, range: 0.4 to 2.1 weeks). SCEMBLIX was temporarily withheld in 2 (0.4%) patients due to anaemia.

Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at <u>www.tga.gov.au/reporting-problems</u>.

4.9 OVERDOSE

There is limited experience of SCEMBLIX overdose. In clinical studies, SCEMBLIX has been administered at doses up to 280 mg twice daily with no evidence of increased toxicity. General supportive measures and symptomatic treatment should be initiated in cases of suspected overdose.

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors. ATC code: L01EA06.

Mechanism of action

Asciminib is an oral and potent inhibitor of ABL/BCR::ABL1 tyrosine kinases. Asciminib inhibits the ABL1 kinase activity of the BCR::ABL1 fusion protein, by specifically targeting the ABL myristoyl pocket.

Pharmacodynamics (PD)

In vitro, asciminib inhibits the tyrosine kinase activity of ABL1 at mean IC₅₀ values below 3 nanomolar. In patient-derived cancer cells, asciminib specifically inhibits the proliferation of cells harbouring BCR::ABL1 with IC₅₀ values between 1 and 25 nanomolar. In cells engineered to express the wild-type or the T315I mutant form of BCR::ABL1, asciminib inhibits cell growth with mean IC₅₀ value of 0.61 ± 0.21 and 7.64 ± 3.22 nanomolar, respectively.

In mouse xenograft models of CML, asciminib dose-dependently inhibited the growth of tumours harbouring either the wild-type or the T315I mutant form of BCR::ABL1, with tumour regression being observed at doses above 7.5 mg/kg or 30 mg/kg twice daily, respectively.

Cardiac electrophysiology

SCEMBLIX treatment is associated with an exposure-related prolongation of the QT interval. The correlation between asciminib concentration and the estimated maximum mean change from baseline of the QT interval with Fridericia's correction (Δ QTcF) was evaluated in 239 patients with Ph+ CML or Ph+ acute lymphoblastic leukaemia (ALL) receiving SCEMBLIX at doses ranging from 10 to 280 mg twice daily and 80 to 200 mg once daily. The estimated mean Δ QTcF was 3.35 ms (upper bound of 90% CI: 4.43 ms) for SCEMBLIX 40 mg twice-daily dose and 3.64 ms (upper bound of 90% CI: 4.68 ms), for the 80 mg once-daily dose and 5.37 ms (upper bound of 90% CI: 6.77 ms) for the 200 mg twice daily dose.

Clinical trials

The clinical efficacy and safety of Scemblix in the treatment of patients with newly diagnosed Philadelphia chromosome-positive myeloid leukemia in chronic phase (Ph+ CML-CP) were demonstrated in the multi-center, randomized, active-controlled and open-label phase III study ASC4FIRST.

In this study, a total of 405 patients were randomized in a 1:1 ratio to receive either Scemblix or investigator selected tyrosine kinase inhibitors (IS-TKIs). Prior to randomization, the investigator selected the TKI (imatinib or second generation [2G] TKI) to be used in the event of randomization to the comparator arm, based on patient characteristics and comorbidities. Patients were stratified according to EUTOS long-term survival (ELTS) risk group (low, intermediate, high), and pre-randomization selection of TKI (imatinib or 2G TKIs stratum). Patients received either Scemblix or IS-TKIs, and continued treatment until unacceptable toxicity or treatment failure occurred.

Patients were 36.8% female and 63.2% male, with median age 51 years (range: 18 to 86 years). Of the 405 patients, 23.5% were 65 years or older, while 6.2% were 75 years or older. Patients were Caucasian (53.8%), Asian (44.4%), Black (1%) and 0.7% unknown. The demographic characteristics within the imatinib (N=203) and the 2G TKIs (N=202) strata were:

- Median age: 55 years and 43 years, respectively;
- ELTS high risk group: 8.4% and 13.9%, respectively;
- Framingham cardiovascular disease high risk group: 35.5% and 17.8%, respectively.

The demographic characteristics were balanced across Scemblix and IS-TKIs, as well as across the two arms within the imatinib and 2G TKIs strata.

Of the 405 patients, 200 received Scemblix, while 201 received IS-TKIs. Of the 201 patients receiving IS-TKIs, 99 received imatinib, 49 received nilotinib, 42 received dasatinib, and 11 received bosutinib. Four patients did not receive any treatment.

The median duration of treatment was 69.8 weeks (range: 0.7 to 107.7 weeks) for patients receiving Scemblix and 64.3 weeks (range: 1.3 to 103.1 weeks) for patients receiving IS-TKIs. By 48 weeks, 90% of patients on Scemblix and 80.6% of patients on IS-TKIs were still receiving treatment.

The study had multiple primary objectives assessing major molecular response rate (MMR) at 48 weeks. One primary objective evaluated Scemblix compared to IS-TKIs. The other primary objective evaluated Scemblix compared to IS-TKIs, within the imatinib stratum. A secondary objective evaluated MMR at 48 weeks evaluating Scemblix compared to IS-TKIs, within the 2G TKIs stratum.

The main efficacy outcomes from ASC4FIRST are summarized in Table 4.

<u> </u>		7 0			/
		IS-TKIs ¹			
Soomblik 90 mg	100-400	mg once or twi	Difforonco		
once daily	All patients (N=204)	lmatinib stratum (N=102)	2G TKIs stratum (N=102)	(95% CI) ²	p-value
ID rate 0/ (050/ Cl) at 49 way	aka				

Table 4 Efficacy results in patients with newly diagnosed Ph+ CML-CP (ASC4FIRST)

MMR rate, % (95% CI) at 48 weeks

	,						
All patients	67.66	49.02			18.88	~0.0013	
(N=201)	(60.72, 74.07)	(41.97, 56.10)			(9.59, 28.17)	×0.001°	
Imatinib stratum	69.31		40.2		29.55	~0.0014	
(N=101)	(59.34, 78.10)		(30.61,50.37)		(16.91, 42.18)	\ 0.001 [·]	
2G TKIs stratum	66			57.84	8.17		
(N=100)	(55.85, 75.18)			(47.66, 67.56)	(-5.14, 21.47)		

Abbreviations: MMR, major molecular response (BCR::ABL1^{IS} ≤ 0.1%); IS-TKIs, investigator-selected tyrosine kinase

inhibitors; 2G TKIs, second generation tyrosine kinase inhibitors; PRS-TKI, pre-randomization selection of TKI.

¹IS-TKIs include imatinib (400 mg once daily) and 2G TKIs, i.e., nilotinib (300 mg twice daily), dasatinib (100 mg once daily) or bosutinib (400 mg once daily).

² Estimated using a common risk difference stratified by PRS-TKI and baseline ELTS risk groups.

³Adjusted p-value using a Cochran-Mantel-Haenszel 1-sided test stratified by PRS-TKI and baseline ELTS risk groups. ⁴Adjusted p-value using a Cochran-Mantel-Haenszel 1-sided test stratified by baseline ELTS risk groups

The predicted MMR rate at 48 weeks for the Scemblix 40 mg twice-daily dose is comparable to

the MMR rate at 48 weeks for the Scentonx 40 ing twice-daily dose is comparable to based on exposure-response analysis.

Median time to MMR in patients receiving Scemblix, IS-TKIs, IS-TKIs within the imatinib stratum, and IS-TKIs within the 2G TKIs stratum were: 24.3 weeks (95% CI: 24.1 to 24.6 weeks), 36.4 weeks (95% CI: 36.1 to 48.6 weeks), 48.6 weeks (95% CI: 36.1 to 59.6 weeks), and 36.1 weeks (95% CI: 24.4 to 48.1 weeks), respectively.

MMR rates at 48 weeks by ELTS risk group in patients receiving Scemblix, IS-TKIs, IS-TKIs within the imatinib stratum, and IS-TKIs within the 2G TKIs stratum were: 72.1%, 57.6%, 50%

and 65.6% for low risk, respectively; 64.3%, 36.8%, 26.7% and 48.2% for intermediate risk, respectively; 52.2%, 31.8%, 12.5% and 42.9% for high risk, respectively.

By 48 weeks, MR4.0 achieved by patients receiving Scemblix, IS-TKIs, IS-TKIs within the imatinib stratum, and IS-TKIs within the 2G TKIs stratum was: 40.8%, 22.1%, 15.7%, and 28.4%, respectively. By 48 weeks, MR4.5 achieved by patients receiving Scemblix, IS-TKIs, IS-TKIs within the imatinib stratum and IS-TKIs within 2G TKIs stratum was: 19.9%, 11.8%, 5.9%, and 17.7%, respectively.

Ph+ CML-CP, previously treated with two or more TKIs

The clinical efficacy of SCEMBLIX in the treatment of patients with Ph+ CML-CP previously treated with two or more tyrosine kinase inhibitors were demonstrated in the multi-centre, randomised, active-controlled and open-label phase III study ASCEMBL.

In this study, a total of 233 patients were randomised in a 2:1 ratio and stratified according to major cytogenetic response (MCyR) status at baseline to receive either SCEMBLIX 40 mg twice daily (N=157) or bosutinib 500 mg once daily (N=76). Patients continued treatment until unacceptable toxicity or treatment failure occurred.

Patients with Ph+ CML-CP previously treated with two or more TKIs were 51.5% female and 48.5% male with median age 52 years (range: 19 to 83 years). Of the 233 patients, 18.9% were 65 years or older, while 2.6% were 75 years or older. Patients were Caucasian (74.7%), Asian (14.2%) and Black (4.3%). Of the 233 patients, 80.7% and 18% had Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, respectively. Patients who had previously received 2, 3, 4, 5 or more prior lines of TKIs were 48.1%, 31.3%, 14.6% and 6%, respectively. The median duration of treatment was 156 weeks (range: 0.1 to 256.3 weeks) for patients receiving SCEMBLIX and 30.5 weeks (range: 1 to 293.3 weeks) for patients receiving bosutinib.

The primary endpoint of the study was MMR at 24 weeks and the key secondary endpoint was MMR rate at 96 weeks. MMR is defined as BCR::ABL1 ratio $\leq 0.1\%$ by International Scale [IS]. Secondary endpoints were complete cytogenetic response rate (CCyR) at 24 and 96 weeks, defined as no Philadelphia-positive metaphases in bone marrow with a minimum of 20 metaphases examined.

The main efficacy outcomes from ASCEMBL are summarised in Table 5.

	SCEMBLIX 40 mg twice daily	Bosutinib 500 mg once daily	Difference (95% CI)	p-value
MMR rate, % (95% CI) at 24 weeks	N=157 25.48 (18.87, 33.04)	N=76 13.16 (6.49, 22.87)	$ \begin{array}{c} 12.24^{1} \\ (2.19, 22.30) \end{array} $	0.029 ²
MMR rate, % (95% CI) at 96 weeks	37.58 (29.99, 45.65)	15.79 (8.43, 25.96)	$21.74^{1} \\ (10.53, 32.95)$	0.001 ²
CCyR rate, % (95% CI) at 24 weeks	N=103 ³ 40.78 (31.20, 50.9)	N=62 ³ 24.19 (14.22, 36.74)	17.3 (3.62, 30.99)	0.019 ^{2,4}
CCyR rate, % (95% CI) at 96 weeks	39.81 (30.29, 49.92)	16.13 (8.02, 27.67)	$23,87^{1}$ (10.3, 37.43)	0.001 ^{2,4}

Table 5Efficacy results in Ph+ CML-CP patients previously treated with two or more
tyrosine kinase inhibitors (ASCEMBL)

¹On adjustment for the baseline major cytogenetic response status

²Cochran-Mantel-Haenszel two-sided test stratified by baseline major cytogenetic response status

³CCyR analysis based on patients who were not in CCyR at baseline

⁴Nominal p-value

The Kaplan-Meier estimated OS rate at 2 years was 97.3% (95% CI: 92.9, 99.0) for the asciminib arm and 98.6% for the bosutinib arm (95% CI: 90.2, 99.8).

The MMR rate at 24 weeks in patients in whom the randomised treatment represented the third, fourth, fifth or more line of TKI was 29.3%, 25%, and 16.1% in patients treated with SCEMBLIX and 20%, 13.8%, and 0% in patients receiving bosutinib, respectively.

The MMR rate at 48 weeks was 29.3% (95% CI:22.32, 37.08) in patients receiving SCEMBLIX and 13.2% (95% CI: 6.49, 22.87) in patients receiving bosutinib. The Kaplan Meier estimated proportion of patients receiving SCEMBLIX and maintaining MMR for at least 120 weeks was 97% (95% CI: 88.6, 99.2).

Ph+ CML-CP harbouring the T315I mutation

The clinical efficacy of SCEMBLIX in the treatment of patients with Ph+ CML-CP with the T315I mutation was evaluated in a multi-centre open-label study CABL001X2101 (NCT02081378). Testing for T315I mutation utilised a qualitative p210 BCR::ABL1 mutation test using Sanger Sequencing.

Efficacy was based on 48 patients with Ph+ CML-CP with the T315I mutation who received SCEMBLIX at a dose of 200 mg twice daily. Patients continued treatment until unacceptable toxicity or treatment failure occurred.

Of the 48 patients, 77.1% were male and 22.9% female; 33.3% were 65 years or older, while 8.3% were 75 years or older with a median age of 56.5 years (range, 26 to 86 years). The patients were White (47.9%), Asian (25%), and Black or African American (2.1%), and 25% were unreported or unknown. Seventy-five percent and 25% of patients had ECOG performance status 0 and 1, respectively. Patients who had previously received 1, 2, 3, 4, and 5 or more TKIs were 16.7%, 31.3%, 35.4%, 14.6%, and 2%, respectively.

MMR was achieved by 24 weeks in 42% (19/45, 95% CI: 27.7-57.8) of the 45 patients treated with SCEMBLIX. MMR was achieved by 96 weeks in 49% (22/45, 95% CI: 34% to 64%) of the 45 patients treated with SCEMBLIX. The median duration of treatment was 108 weeks (range, 2 to 215 weeks).

5.2 Pharmacokinetic properties

Absorption

Asciminib is rapidly absorbed, with median maximum plasma levels (Tmax) reached 2 to 3 hours after oral administration, independent of the dose. The geometric mean (geoCV%) of Cmax at steady state is 1781 ng/ml (23%) and 793 ng/ml (49%) following administration of SCEMBLIX at 80 mg once-daily and 40 mg twice-daily doses, respectively. The geometric mean (geoCV%) of Cmax at steady state is 5642 ng/ml (40%) following administration of SCEMBLIX at 200 mg twice daily dose. The geometric mean (geoCV%) of AUCtau is 5262 ng*h/ml (48%) following administration of SCEMBLIX at 40 mg twice-daily dose.

PBPK models predict that the asciminib absorption is approximately 100%, while bioavailability is approximately 73%.

Asciminib bioavailability may be reduced by co-administration of oral medicinal products containing hydroxypropyl- β -cyclodextrin as an excipient. Co-administration of multiple doses of itraconazole oral solution containing hydroxypropyl- β -cyclodextrin at a total of 8 g per dose with a 40 mg dose of asciminib, decreased asciminib AUCinf by 40.2% in healthy subjects.

Food effect

Food consumption decreases asciminib bioavailability, with a high-fat meal having a higher impact on asciminib pharmacokinetics than a low-fat meal. Asciminib AUC is decreased by 62.3% with a high-fat meal and by 30% with a low-fat meal compared to the fasted state, independent of the dose (see section 4.2 Dose and method of administration and section 4.5 Interactions with other medicines and other forms of interactions).

Distribution

Asciminib apparent volume of distribution at steady state is 111 L, based on population pharmacokinetic analysis. Asciminib is mainly distributed to plasma, with a mean blood-to-plasma ratio of 0.58, independent of the dose. Asciminib is 97.3% bound to human plasma proteins, independent of the dose.

Metabolism

Asciminib is primarily metabolised via CYP3A4-mediated oxidation (36%), UGT2B7- and UGT2B17-mediated glucuronidation (13.3% and 7.8%, respectively). Asciminib is the main circulating component in plasma (92.7% of the administered dose).

Excretion

Asciminib is mainly eliminated via fecal excretion, with a minor contribution of the renal route. Eighty and 11% of the asciminib dose were recovered in the feces and in the urine of healthy subjects, respectively, following oral administration of a single 80 mg dose of $[^{14}C]$ -labelled asciminib. Fecal elimination of unchanged asciminib accounts for 56.7% of the administered dose.

The oral total clearance (CL/F) of asciminib is 6.31 L/hour, based on population pharmacokinetic analysis. The accumulation half-life of asciminib is 5.2 hours at 40 mg twice daily and 80 mg once daily.

PBPK models predict that asciminib biliary secretion via BCRP accounts for 31.1% of its total systemic clearance.

Linearity/non-linearity

Asciminib exhibits a slight dose over-proportional increase in steady-state exposure (AUC and Cmax) across the dose range of 10 to 200 mg administered once or twice daily.

The geometric mean average accumulation ratio is approximately 2-fold, independent of the dose. Steady-state conditions are achieved within 3 days at the 40 mg twice-daily dose.

Special populations

Use in elderly patients (65 years of age or above)

Among the 556 patients receiving SCEMBLIX in the ASC4FIRST, ASCEMBL and X2101 studies, 130 (23.4%) patients were 65 years or older, and 31 (5.6%) were 75 years or older.

No overall differences in the safety or efficacy of SCEMBLIX were observed between patients of 65 years of age or above and younger patients. There is an insufficient number of patients of 75 years of age or above to assess whether there are differences in safety or efficacy.

Gender/Race/Body weight

Asciminib systemic exposure is not affected by gender, race or body weight to any clinically relevant extent.

Renal impairment

A dedicated renal impairment study including 6 subjects with normal renal function (absolute glomerular filtration rate [aGFR] \geq 90 mL/min) and 8 subjects with severe renal impairment not requiring dialysis (aGFR 15 to <30 mL/min) has been conducted. Asciminib AUCinf and Cmax are increased by 56% and 8%, respectively, in subjects with severe renal impairment compared to subjects with normal renal function, following oral administration of a single 40 mg dose of SCEMBLIX (see section 4.2 Dose and method of administration).

Population pharmacokinetics models indicate an increase in asciminib median steady state AUC_{0-24h} by 11.5% in subjects with mild to moderate renal impairment, compared to subjects with normal renal function.

Hepatic impairment

A dedicated hepatic impairment study including 8 subjects each with normal hepatic function, mild hepatic impairment (Child-Pugh A score 5 to 6), moderate hepatic impairment (Child-Pugh B score 7 to 9) or severe hepatic impairment (Child-Pugh C score 10 to 15) was conducted. Asciminib AUCinf is increased by 22%, 3% and 66% in subjects with mild, moderate and severe hepatic impairment, respectively, compared to subjects with normal hepatic function, following oral administration of a single 40 mg dose of SCEMBLIX (see section 4.2 Dose and method of administration).

5.3 PRECLINICAL SAFETY DATA

Asciminib was evaluated in safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenicity, reproductive toxicity and phototoxicity studies.

Genotoxicity

Asciminib was negative for genotoxicity in a bacterial reverse mutation assay, *in vitro* micronucleus assays in lymphocytes and TK6 cells and in vivo, in a rat micronucleus assay at PO doses up to 600 mg/kg/day.

Carcinogenicity

The carcinogenic potential of asciminib was investigated in a 2-year study by the oral route in rats. Benign ovarian Sertoli cell tumours were observed in female animals at 66 mg/kg/day (yielding exposure to asciminib 8- and 6-fold higher than in patients at 40 mg twice daily and 80 mg once daily, respectively, and comparable to that in patients with dosing at 200 mg twice daily, based on plasma AUC). This occurred in conjunction with increased ovarian Sertoli cell hyperplasia (observed with treatment at \geq 30 mg/kg/day). The clinical relevance of the finding is currently unknown. No treatment-related neoplastic or hyperplastic findings were observed in male rats up to the highest dose tested (200 mg/kg/day; yielding exposure 18, 12 and 2.5 times

higher, respectively, than in patients treated at 40 mg twice daily, 80 mg once daily and 200 mg twice daily).

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

SCEMBLIX tablets contain the following inactive ingredients:

• 20 mg film-coated tablets: Lactose monohydrate, microcrystalline cellulose (E460i), hydroxypropylcellulose (E463), croscarmellose sodium (E468), polyvinyl alcohol (E1203), titanium dioxide (E171), magnesium stearate, talc (E553b), colloidal silicon dioxide, iron oxide (E172, yellow and red), lecithin (E322), xanthan gum (E415).

• **40 mg film-coated tablets:** Lactose monohydrate, microcrystalline cellulose (E460i), hydroxypropylcellulose (E463), croscarmellose sodium (E468), polyvinyl alcohol (E1203), titanium dioxide (E171), magnesium stearate, talc (E553b), colloidal silicon dioxide, iron oxide (E172, black and red), lecithin (E322), xanthan gum (E415).

6.2 INCOMPATIBILITIES

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store below $25^{\circ}C$ – blister packs.

Store below $30^{\circ}C$ – bottles.

Store in the original package in order to protect from moisture.

6.5 NATURE AND CONTENTS OF CONTAINER

SCEMBLIX tablets are supplied in HDPE bottles or PCTFE/PVC/Alu blisters*.

SCEMBLIX 20 mg tablets:

Supplied in blister packs or bottles containing 20 or 60 tablets.*

SCEMBLIX 40 mg tablets:

Supplied in blister packs or bottles containing 20 or 60 tablets or in bottles containing 300 tablets.*

*Not all pack sizes and container types may be marketed

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 PHYSICOCHEMICAL PROPERTIES

Asciminib hydrochloride has a molecular formula $C_{20}H_{18}ClF_2N_5O_3$.HCl; the free base has a molecular weight of 449.8. Asciminib HCl is a crystalline powder with pKa 3.9 and pH-dependent solubility.

Chemical structure



CAS number

2119669-71-3.

7 MEDICINE SCHEDULE (POISONS STANDARD)

Schedule 4 - Prescription Only Medicine

8 <u>SPONSOR</u>

NOVARTIS Pharmaceuticals Australia Pty Limited ABN 18 004 244 160 54 Waterloo Road Macquarie Park NSW 2113 Telephone 1800 671 203 Web site: <u>www.novartis.com.au</u> ® = Registered Trademark

9 DATE OF FIRST APPROVAL

15 July 2022

10 DATE OF REVISION

9 July 2025

Summary table of changes

Section changed	Summary of new information
4.1, 4.4, 4.8, 5.1, 5.2	Addition of data from Study J12301

Internal document code: Sce010725i is based on CDS dated 4 December 2024